Who is it for?
- ER-positive, HER2-negative invasive primary breast cancer
- 0–3 positive lymph nodes, tumour size pT1–3, grade G1–3
- Pre- or postmenopausal patients
- Cases where the chemotherapy decision is unclear based on clinical factors
What is in your report?
Three clinical questions in a single test
Genes analysed
12 genes8 target genes (BIRC5, UBE2C, DHCR7, RBBP8, IL6ST, AZGP1, MGP, STC2), 3 normalisation genes (CALM2, OAZ1, RPL37A) and 1 control gene (HBB).
Technical details
- Method
- Gene expression (RNA) by RT-PCR
- Sample
- 10 µm sections from FFPE tumour tissue; tumour content of at least 30%; prior to systemic treatment
- Turnaround time
- Usually within 1 week
- Scores
- 12-gene molecular score (0–15) and EPclin risk score (1–6); the 3.3287 cut-off corresponds to a 10% risk of distant recurrence at 10 years
- Evidence
- Validated in 4 prospective-retrospective studies (ABCSG-6, ABCSG-8, GEICAM/9906, TransATAC); included in the NCCN, ASCO, ESMO and St. Gallen guidelines
- Manufacturer
- Myriad Genetics — CE-IVD marked in Europe
Included with your report
- EPclin score and low / high risk category
- Probability of distant recurrence at 0–10 years (with endocrine therapy alone)
- 10-year absolute benefit of chemotherapy
- Probability of late distant recurrence at 5–15 years
How does the process work?
- 1Leave your request
Choose the test, or let your physician request it on your behalf. If you are not sure which test fits, we decide together.
- 2We call you
Our team calls within 1 working day to confirm the request, the sample type (blood or tumour tissue) and your appointment time.
- 3Sample collection
A blood sample is taken at Akasya Partner Clinics in a few minutes. For tissue tests, the pathology block is collected by courier.
- 4Report and review
The report is ready in 1–6 weeks depending on the test (stated on each test page), sent to your physician and reviewed with our consultant physicians.

